Browse > Article

Evaluation of the Current Regimen of Tacrolimus in Patients with Hematopoietic Stem Cell Transplantation  

Yeo, Mi-Jin (Department of Pharmacy, Seoul St. Mary's Hospital, The Catholic University of Korea)
Park, Soo-Jin (Department of Pharmacy, Seoul St. Mary's Hospital, The Catholic University of Korea)
Bang, Joon-Seok (Department of Pharmacy, Seoul St. Mary's Hospital, The Catholic University of Korea)
La, Hyen-Oh (Department of Pharmacy, Seoul St. Mary's Hospital, The Catholic University of Korea)
Publication Information
Korean Journal of Clinical Pharmacy / v.20, no.3, 2010 , pp. 193-199 More about this Journal
Abstract
Tacrolimus, an immunosuppressant prescribed against graft-versus-host disease (GVHD) in patients with allogeneichematopoietic stem cell transplantation (HSCT), is affected to change its pharmacokinetic properties by various factors. For this reason, it is needed a close monitoring to adjust dosage amount in order to optimize the blood concentration of tacrolimus is located within the effective range. According to our in-house study, 62% of HSCT-patients were needed dosage-adjustment and it is necessary to optimize the current immunosuppressive regimen in clinical settings. A retrospective study was designed to evaluate the dosing regimen (converting ratio of IV:PO=1:4) of tacrolimus in HSCT patients (n=62). After collecting data from patient's profile and medical record, pharmacokinetic parameters were calculate and compared between the estimated and the actual values in the selected subjects (n=58). It was found that the bioavailabilty (BA) of oral tacrolimus was 40.5% very much different from that is known as 25%. It implies that the current protocol has a potent risk causes dose-related toxicities to the patients. Furthermore, analyses among factors demonstrated that there was no statistical significance between BA of tacrolimus and the variable factors. In the clinical perspectives, the current converting ratio of tacrolimus in patients with HSCT to be re-considered and an appropriate and optimal alternative regimen should be adopted to prevent GVHD and to increase the quality of life of patients.
Keywords
bioavailability; HSCT; GVHD; immunosuppressant; tacrolimus; TDM;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Rowland M, Tozer T. Clinical pharmacokinetics: Concepts and applications. 3rd ed. Baltimore, Williams & Willkins, 1995; 290-309, 313-339.
2 Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets and side effects. New Eng J Med 2003; 348: 538-49.   DOI   ScienceOn
3 MacPhee IA, Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and p-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-9.   DOI   ScienceOn
4 Scott LJ, McKeage K, Keam SJ, et al., Taclorimus: A further update of its use in the management organ transplantation. Drugs 2003; 63: 1247-97.   DOI   ScienceOn
5 Jusko WJ, Piekoszewski W, Klintmalm GB, et al., Pharmacokinetics and of tacrolimus in liver transplant patients. Clin pharmacol Ther 1995; 57: 281-90.   DOI   ScienceOn
6 Bekersky I, Dressler D, Alak A, et al., Comparative tacrolimus pharmacokinetics: Normal versus midly hepatically impaired subjects. J Clin Pharmacol 2001; 41: 628-35.   DOI   ScienceOn
7 Gaston S. Maintenance immunosuppression in the renal transplant recipient. An overview. Am J Kidney Dis 2001; 38: S25-S35.   DOI   ScienceOn
8 Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens 2003; 11: 657-63.
9 Mekki Q, Lee C, Aweeka F, et al., pharmacokinetics of tacrolimus (FK506) in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 238.
10 Boswell GW, Bekersky I, Fay J, et al., Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998; 21: 23-8.   DOI   ScienceOn
11 Quan D, Winter ME. Immunosuppressants: Cyclosporine, tacrolimus, and sirolimus, In: Basic clinical pharmacokinetics. 4th ed. Baltimore, MD, Lippincortt Williams & Wilkins, 2004: 228-250.
12 Cattanneo D, Perico N, RemuzzinG. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive. Am J Transplant 2004; 4: 299-310.   DOI   ScienceOn
13 Yagil Y, Yagil C. Pharmacogenomic considerations for immunosuppressive therapy. Pharmacogenomics 2003; 4: 309-13.   DOI   ScienceOn
14 Weinshilboum R. Inheritance and drug response. New Eng J Med 2003; 348: 529-37.   DOI   ScienceOn
15 Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000; 14: 190-204.   DOI   ScienceOn
16 Hiraoka A. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogenic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181-5.   DOI   ScienceOn
17 Ferarra JL. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol 2008; 21: 677-82.   DOI
18 Fay JW, Wingard JR, Antin JH, et al., FK506 (Tacrolimus) monotherapy for prevention of Graft-Versus-Host Disease After Histocompatible Sibling Allogenic Bone Marrow Transplantation. Blood 1996; 87: 3514-9.
19 Simpson D. Drug therapy for acute graft-versus-host disease prophylaxis. J Hemato Ther Stem Cell Res 2000; 9: 317-25.   DOI   ScienceOn
20 Lesley S. Tacrolimus, A further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-97.   DOI   ScienceOn
21 Yanada M. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34: 331-7.   DOI   ScienceOn
22 Jusko WJ, Thomson AW, Fung J, et al., Consensus document: therapeutic drug monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17: 606-14.   DOI   ScienceOn
23 Staatz CE, Willis C, Taylor PJ, et al., Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin pharmacol Ther 2002; 72: 660-9.   DOI   ScienceOn
24 Felipe CR, Silva HT, Machado PG, et al., The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics ad therapeutic drug monitoring. Clin Transplant 2002; 16: 262-72.   DOI   ScienceOn
25 Park K. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther 2007; 29: 154-62.   DOI   ScienceOn